Cargando…

Editorial: Biological drugs and biosimilars in autoimmune diseases

Detalles Bibliográficos
Autores principales:	Wajda, Anna, Perricone, Carlo, Kashyap, Anniruddh, Iliyasu, Mahmud Yerima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018160/ https://www.ncbi.nlm.nih.gov/pubmed/36937853 http://dx.doi.org/10.3389/fphar.2023.1168972

Ejemplares similares

Editorial: Autoimmune and Inflammatory Rheumatic Diseases: Identifying Biomarkers of Response to Therapy With Biologics
por: Giuliani, Anna Lisa, et al.
Publicado: (2021)

Editorial: Autoimmune and inflammatory rheumatic diseases: Identifying biomarkers of response to therapy with biologics: Volume II
por: Giuliani, Anna Lisa, et al.
Publicado: (2023)

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
por: Baumgart, Daniel C., et al.
Publicado: (2019)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Creating China’s Biosimilar Drugs Regulatory System: A Calculated Approach
por: Yang, Jianhong, et al.
Publicado: (2022)

Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
por: Li, Ping, et al.
Publicado: (2017)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Assessment of expenditure control and prescriptive appropriateness of biological drugs in autoimmune diseases and chronic inflammatory bowel disease
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Editorial: Innovative Biologics and Drugs to Target Renal Inflammation
por: Griffin, Matthew D., et al.
Publicado: (2020)

Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease
por: Wu, Guozhi, et al.
Publicado: (2021)

Editorial: Therapeutic Implications for Pregnant Women With Systemic Autoimmune Diseases and Their Children
por: Chighizola, Cecilia Beatrice, et al.
Publicado: (2021)

Editorial: Medicinal plants as a source of novel autoimmune-modulating and anti-inflammatory drug products
por: Wang, Yang, et al.
Publicado: (2022)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis
por: Hu, Rui, et al.
Publicado: (2023)

Editorial: Bypassing the Biological Barriers by Means of Biocompatible Drug Delivery Systems
por: Awasthi, Vibhudutta, et al.
Publicado: (2021)

Editorial: Circadian biology, cardiovascular function and disease
por: Chong, Nelson, et al.
Publicado: (2023)

Editorial: Pharmacology of autoimmune and neuroinflammatory disease from a preclinical and clinical perspective
por: Šíma, Martin, et al.
Publicado: (2023)

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
por: Colloca, Luana, et al.
Publicado: (2019)

“Biosimilar, so it looks alike, but what does it mean?” A qualitative study of Danish patients' perceptions of biosimilars
por: Varma, Meera, et al.
Publicado: (2022)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Editorial: Advances in drug-induced diseases
por: Liu, Yao, et al.
Publicado: (2023)

An international comparative analysis and roadmap to sustainable biosimilar markets
por: Alnaqbi, Khalid A., et al.
Publicado: (2023)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
por: Spanou, Ioanna, et al.
Publicado: (2019)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Intensive Safety Monitoring of Rituximab (Biosimilar Novex(®) and the Innovator) in Pediatric Patients With Complex Diseases
por: Riva, Natalia, et al.
Publicado: (2022)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
por: Huang, Hui-Yao, et al.
Publicado: (2020)

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Editorial: New insights into pathophysiology and management of pregnancy in systemic autoimmune diseases: Toward new therapeutic approaches
por: Bettiol, Alessandra, et al.
Publicado: (2022)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases
por: Mokry, Juraj, et al.
Publicado: (2021)

Editorial: Progresses in the Drug Treatment of Chronic Cardiopulmonary Diseases
por: Li, Xiaohui, et al.
Publicado: (2022)

Editorial: Nanomedicine in Infectious Diseases: Drug Delivery and Vaccines
por: Marepally, Srujan, et al.
Publicado: (2022)

Editorial: Drugging p53 for non-cancer diseases
por: Jiang, Fan, et al.
Publicado: (2022)

Editorial: Drug-drug interactions in pharmacology
por: Pichini, Simona, et al.
Publicado: (2023)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
por: Wang, Fang, et al.
Publicado: (2023)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Genetic Factors of Autoimmune Diseases
por: Ceccarelli, Fulvia, et al.
Publicado: (2016)

Editorial: The challenges of drug repurposing in diseases related to chronic inflammation
por: Collotta, Debora, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mig4trl01topl81ki5f673d1p9